Mirum Pharmaceuticals, Inc. (MIRM) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Foster City, CA, 미국. 현재 CEO는 Christopher Peetz.
MIRM 을(를) 보유 IPO 날짜 2019-07-18, 334 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $4.86B.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for rare and orphan diseases affecting the liver and bile system. The company's lead product candidate, LIVMARLI, is an investigational oral medication designed to treat progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. Mirum also develops Volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018 and headquartered in Foster City, California, Mirum focuses on addressing critical unmet needs in hepatobiliary diseases.
